RxDoctor Payments Data

Vitaliy Volansky, DPM

Foot Surgery · Boston, MANPI 1679703151

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,079 of the $1,415 with a category attached, or 76.2%. 12 manufacturers reported payments, led by Integra Lifesciences Corporation at 32.7% of the total. Reporting peaked in 2024 at $550 and has fallen 75.4% since, to $135 in 2025.

$1,415in general payments, 2019–2025

Across 19 payments — averaging $74.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$463
  • Acera Surgical, Inc.$222
  • Mimedx Group, Inc.$166
  • Kairos Surgical Inc$136
  • Stryker$129
  • Zimmer Biomet$102
  • plus $197 from 6 others
$391,168in research payments, 2019–2025

Across 44 payments — averaging $8890.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$149K
  • Convatec Inc.$137K
  • Acera Surgical, Inc.$78K
  • Reddress LTD$26K

What the payments were for

  • Food & beverage$1,07976%
  • Other$33724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,415 in reported general payments places this provider in the 70th percentile of 41 foot surgery providers in Massachusetts.

See all foot surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$46,318
Medicare patients
206
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium126$5,030
Econazole Nitrate40$1,383
Ciclopirox49$1,021
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip52$855
Ammonium Lactate54$641
Ketoconazole19$561
Tramadol Hcl19$54

Paid to pharmacies, not to this prescriber.

Other foot surgery in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →